ArticleInternational journal of nanomedicine2023
Sustained-Release Esketamine Based Nanoparticle-Hydrogel Delivery System for Neuropathic Pain Management.
Article in International journal of nanomedicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Multimodal opioid-free anesthesia containing esketamine versus opioid-based anesthesia: a systematic review and meta-analysis.BMC anesthesiology · 2026Pooled it
- Ketamine treatment alleviates suicide ideation in high-risk populations: a systematic review and meta-analysis.Epidemiology and psychiatric sciences · 2026Pooled it
- Precision application of target-controlled infusion of esketamine combined with sufentanil in anesthesia for thoracoscopic surgery and its effect on hemodynamics, postoperative pain, and safety.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Trial
- Clinical innovations and future directions of nanoparticles in the treatment of psychiatric and neurological disorders.Molecular psychiatry · 2026Review
- Optimized mucus adhesion and penetration of lipid-polymer nanoparticles enables effective nose-to-brain delivery of perillyl alcohol for glioblastoma therapy.Drug delivery and translational research · 2026Article
- Untangling neuropathic pain: pathophysiological insights and future directions for targeted therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- From Printability to Biofunctionality: 3D-Printed Hydrogel Scaffolds for Multi-Tissue Engineering.Gels (Basel, Switzerland) · 2026Review
- Targeting microglial circMBNL1 unlocks a novel nanomedicine therapeutic strategy for major depressive disorder.Journal of nanobiotechnology · 2026Article
- Development of Nigella sativa essential oil loaded keratin/gelatin cryogel with antimicrobial and antioxidant properties for wound dressing.Scientific reports · 2026Article
- Docosahexaenoic Acid Attenuates Visceral Pain by Suppressing Spinal CXCL10/CXCR3/ERK Signaling.Nutrients · 2026Article
- Hydrogels-Advanced Polymer Platforms for Drug Delivery.Polymers · 2026Review
- Esketamine Alleviates Neuropathic Pain and Inflammation via miR-153-3p/AKT3 in CCI Rats.Pain research & management · 2026Article
- Precise delivery and controlled release: strategies and advances in TLR7/8 agonist prodrugs for cancer immunotherapy.Frontiers in immunology · 2026Review
- Research on the Inhibition of Cancer Cell Metastasis by Graphene Oxide Suppresses the Translation of the Snail mRNA.International journal of nanomedicine · 2026Article
- Hydrogel-Based Delivery Systems for Non-Opioid Analgesics: Advances, Challenges, and Clinical Prospects.Journal of clinical medicine · 2025Review
- Printable Conductive Hydrogels and Elastomers for Biomedical Application.Gels (Basel, Switzerland) · 2025Review
- Dorsal root ganglion-targeted analgesic delivery for effective relief of neuropathic pain.Materials today. Bio · 2025Article
- Efficacy of Intranasal Esketamine in Treatment-Resistant Depression: A Six-Month Real-World Follow-Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk.Human psychopharmacology · 2025Article
- Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials.The journal of headache and pain · 2025Review
- The Role of Intravenous Anesthetics for Neuro: Protection or Toxicity?Neuroscience bulletin · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Esketamine, one of the few non-opioid potent analgesics, has demonstrated efficacy in the treatment of various chronic pain, particularly neuropathic pain. However, its potential clinical applications are confined due to its short half-life and severe side effects including delirium, hallucinations, and other psychiatric symptoms. Here, we reported a nanosized drug delivery system for sustained-release esketamine based on polylactic-co-glycolic acid (PLGA) nanoparticles and hyaluronic acid (HA) hydrogel. Results: In this study, esketamine in the delivery system was continuously released in vitro for at least 21 days, and spinal nerve root administration of the delivery system successfully attenuated (spinal nerve ligation) SNL-induced pain hypersensitivity for at least 14 days. Notably, the excitability of neurons in murine dorsal root ganglion (DRG) was inhibited and the activation of astrocytes in the spinal cord was additionally reduced after administration. Finally, there was no obvious pathophysiological change in the nerves at the administration site after treatment at 14 days. Conclusion: These results indicate that the sustained-release esketamine based on the nanoparticle-hydrogel delivery system can safely produce a lasting analgesic effect on SNL mice, and its mechanism might be related to modulating the activation of astrocytes in the spinal cord and inhibiting the excitability of neurons in DRG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.